Mantis Therapeutics is a company developing an innovative targeted immunotherapy against cancer. This therapy is based on a conditional attenuated Salmonella enterica serovar Typhimurium vector that specifically targets and colonizes solid tumors.
The conditional attenuated vector is engineered to have a triple action mechanism: it can colonize and directly kill the tumor, it can stimulate the immune system to kill the tumor and can it can potentially deliver anti-cancer molecules inside the tumor.
The attenuation level of our vector can be remotely controlled by administration of a sugar to patients. Mantis Therapeutics expects that this innovative approach will allow us to tightly control the balance between safety and efficacy, resulting in the best results in the clinic. We have achieved proof of concept on pre-clinical models of cancer.